

Intrauterine Fetal Demise

The value of a work up in the setting of a stillbirth after 20 weeks is for counseling for future pregnancies, possibly to reduce the risk of subsequent stillbirths, to decrease morbidity, to facilitate emotional closure for the woman and her family, (Silver 2010) and for humanitarian reasons so that, according to McPherson, families know that their child is valued. From a public health and scientific perspective, a systematic evaluation of the circumstances and associations with stillbirths may assist in investigations that could lead to preventive strategies.

When counseling patients in these circumstances, it is important to communicate that even with a complete evaluation, that some cases remain unexplained. The work up needs to consider both the potential cost and the potential for yield from the work up. A standard medical, surgical, psychological and obstetrical history is critical. Attached there is a recommended questionnaire to use as a template (Silver 2010) that is recommended for all cases.

There are some assessments in addition to the thorough history described that should be offered and hopefully included in assessments of all still births.

Assessments for all stillbirths

1. Description of the fetus and placenta by the delivering provider.
 - a. Fetal and placental weight
 - b. Foot length
 - c. Gestational age
 - d. Description of cord
 - i. Position
 - ii. Number of vessels
 - iii. Any visible abnormalities
 - iv. Insertion site on placenta (Central, marginal, velamentous)
 - v. Any irregularities (compression, etc)
 - vi. Length of cord
 - vii. Degree of coiling
 - a. Cord coiling: >0.3 coils/cm considered hypercoiled: seen in 37% of stillbirths. < 0.1/cm: decreased. 29% of stillbirths
 - e. Placental description
 - i. Adherent clot, membrane opacity, infarcts, other irregularities?
 - ii. Meconium
 - f. Fetus description
 - i. Degree of maceration



- i. External description including face, limbs, spine, genitalia, patency of anus, palate. If dysmorphic features are noted, consider genetic consultation for formal dysmorphology exam.
 - ii. Gender assignment with caution
2. Placental pathology
 - a. Vasculature
 - b. Evidence of infection
 - c. Histology
 - d. Abnormalities
 - e. Evidence of hypoxia
 - f. Multifetal placentation, vasculature
3. Autopsy
 - a. Counseling: 26-51% of the time, an autopsy reveals important information with respect to counseling, future pregnancies (Silver, 2010)
 - b. There is **no cost** for an autopsy when a patient has had care at UNC Hospital (<https://www.unccmedicalcenter.org/mclendon-clinical-laboratories/directory/autopsy-service/>)
 - c. Looking specifically for evidence of infection, anemia, hypoxia, metabolic abnormalities, birth defects, estimate of time demise to delivery.
 - d. Discuss history with pathologist
 - e. If patient declines autopsy, request to have dysmorphologist examine fetus in the morgue; MRI post mortem; partial autopsy
 - f. MRI for stillborn fetus
 - i. Order the MRI (IMG5834)
 - ii. Let the patient's nurse know that the MRI needs to happen BEFORE the fetus is taken to any other location
 - iii. Request that the nurse call MRI and arrange for transport to pick-up the fetus then return it to L&D.

*Ideally, the MRI should be done before leaving L&D
4. Karyotype and microarray
 - a. 8-13% of all stillbirths; 20% with IUGR or anomalies
 - b. Amniocentesis much preferred to post-delivery tissue.**

Cytogenetic success rates were significantly higher for invasive testing pre-delivery (85%) than for postpartum tissue analysis (28%, P<.001) [Korteweg FJ , 2008, Obstetrics and Gynecology]
 - c. Microarray yields results more often than karyotype analysis** (Reddy, 2012).

However, most stillbirths due to a genetic abnormality are still due to the most common aneuploidies (trisomy 18, 13, 21, monosomy X) **we therefore recommend karyotype (20 cell) with reflex to microarray.**
 - d. Pre-test counseling points to consider: microarray costs more, microarray can result in variants of uncertain significance, can reveal low penetrance, adult onset conditions, consanguinity, microarray cannot detect mechanism of aneuploidy (non-disjunction vs. Robertsonian translocation).**
 - e. A genetic counseling appointment can be made post-delivery preferably at least 6 weeks after loss to discuss results of cytogenetic testing sent in cases of stillbirth.



Place ambulatory referral to reproductive genetics in EPIC if desired.

- f. **First tier sample:** Amniocentesis (EPIC order LAB5501): Obtain 30mL of amniotic fluid (90 mL if procedure is due to polyhydramnios). Place “Cytogenetics Prenatal/FISH” order (LAB5501). Default to “Unit collect”, “Save cells” if additional genetic testing may be indicated. Click on what testing is desired in “add Cytogenetics Order”. **If ordering microarray in fetus that is female or of unknown sex you must also order Maternal Cell Contamination testing (LAB6039).**

Cytogenetics Prenatal ✓ Accept ✗ Cancel

Status:

Expected Date: Approx.

Expires:

Priority:

Class:

Lab: Resulting Agency: Collection Date: Collection Time:

Add Cytogenetics Order: Karyotype and Microarray

Have you ordered Maternal Cell Contamination Testing (LAB6039)?

Indication for Amnio/ CVS: IUFD

Indication Comments:

Routine AF/AFP:

Save Cells:

- g. **Second tier samples:** Products of conception: Obstetrician should offer to send post-delivery tissue if invasive testing was declined/not performed pre-delivery. It is optimal to send as **many sources of tissue** as possible if an amniocentesis was not performed.
- i. First tier tissues: Placenta
 1. Collect several ~10 mm pieces of the chorion containing villi in **thawed** culture medium
 - ii. Second tier tissues: Cord blood or umbilical cord tissue
 1. Blood from umbilical cord: Ideally, 3 mL should be placed in a Sodium heparinized tube (green top).
 2. 2-3 cm umbilical cord in **thawed** culture medium
 - ii. If autopsy requested: Deep fetal tissue can be sent
 1. Deep fetal tissue: Pathology requisition should request deep fetal tissue at time of fetal processing during autopsy.
 2. This often has the lowest yield depending on time since demise occurred

Products of conception (LAB5505): Obtain a cytogenetics specimen collection medium (pink) from freezer on L&D or Core Lab. Place several ~10 mm pieces of the chorion containing villi in the tube of **thawed** culture medium. Can also place 2-3 cm umbilical cord in a second container of thawed culture medium. Submerge the tissue completely in the medium. **DO NOT PLACE SAMPLE IN FORMALIN, PLACE IN UNTHAWED MEDIA, OR SEND IN SALINE** since viable cells are needed for karyotyping. Send specimen with orders (Cytogenetics Postnatal/FISH) immediately to Core Lab. Do not freeze. Do not refrigerate. **If ordering microarray in fetus that is female or of unknown sex you must also order Maternal Cell Contamination testing (LAB6039).**

Cyto genetics Postnatal/FISH ✓

Status:

Expected Date: 5/20/2019 Approx.

Expires: 6/20/2019

Priority:

Class:

Lab: Resulting Agency: Collection Date: Collection Time:

SOURCE

Is patient or close relative pregnant?

What is the gestational age of pregnancy? EDD =

Please specify suspected chromosome abnormality

Indication for Study (Clinical features/ family history)

Developmental delay/intellectual disability Dysmorphic features Autism Seizure disorder

Short stature Suspect trisomy (specify) Major Birth Defects Multiple congenital anomalies

Familial follow up (Specify) Other (Specify)

Studies Requested

5. Assessment for fetal-to-maternal hemorrhage
 - a. 3-14% of all stillbirths
 - b. Massive hemorrhage (>20% of blood volume)
 - c. Recommend fetal bleed screen prior to induction; can be done up to 2-3 weeks post delivery.
6. Indirect Coombs (if not completed earlier in pregnancy)
 - a. If not performed during this pregnancy
 - b. Repeat only if fetus is hydropic.
7. Toxicology Screen



- a. Maternal serum or urine; fetal tissues such as meconium, hair or cord
8. Infectious work up
- a. Up to 20% in cases < 28 weeks.
 - b. Parvo B 19: up to 8% of stillbirths based on viral nucleic acid in placenta
 - c. Syphilis
 - d. Without clinical or histologic evidence, TORCH infection w/u is of unproven utility.
9. Thrombophilia
- a. Lupus anticoagulant IgG and IgM
 - b. Beta 2 Glycoprotein antibody
 - i. 40 mpl/gpl or >99thth percentile considered positive (confirmatory study will be repeated at 12 weeks if positive)
 - Low titers and Pos IgA isotype of uncertain significance
 - Most likely if + preeclampsia and or PE
 - c. Antiphospholipid antibodies
 - d. Other thrombophias if severe placental pathology, IUGR, history thrombosis
 - e. Do not recommend Factor V leiden, prothrombin gene mutation, protein C and S, unless family history.
 - f. Do not recommend MTHFR
10. Consideration in Some Stillbirths
1. History of pruitutus: check bile acids, LFTs
 2. History of PPRM, cervical insufficiency, preterm labor or Malpresentation
 - a. Consider uterine abnormalities
 - b. Interval hysterosonography or MRI or HSG
 3. Glucose, thyroid testing
 4. Antithrombin III; Protein C and S 6 weeks
 5. Creatinine
11. Generally not useful
1. ANA
 2. TORCH
12. Additional things to consider
- Photos
 - Grief counseling
 - Social work
 - Pastoral care
 - Follow up



TABLE 1. Essential Components of History

Details of the current pregnancy
Maternal age
Gestational age (supportive evidence including sonograms)
Medical conditions complicating pregnancy
Pregnancy-induced hypertension
Gestational diabetes
Cholestasis of pregnancy
Viral illness
Multifetal gestation
Known pregnancy complications
Preterm labor
Rupture of membranes
Fetal structural or chromosomal abnormalities including abnormal serum screening
Infections
Trauma
Abruptio
Maternal symptoms suggestive of above complications
Maternal serum marker screen
Maternal medical history
Chronic illnesses
Diabetes
Thyroid disease
Autoimmune disease
Hypertension
Cardiopulmonary disease
History of pertinent acute conditions
Prior venous thromboembolism
Substance use
Known genetic abnormalities
Balanced translocations
Single gene mutations
Pregnancy history
Recurrent miscarriages
Previous stillbirth or neonatal demise
Previous pregnancy complicated by
Growth restriction
Hypertension
Fetal anomalies
Abruptio
Family history
Developmental delay or mental retardation
Stillbirth or recurrent miscarriage
Genetic syndromes
Significant medical illnesses (pulmonary embolism and severe hypertension)



All Stillbirths

1. Complete History (see example)
2. Description of fetus, cord and placenta by delivering provider
3. Encourage autopsy
 - a. If declines, consider MRI
4. For losses >20 weeks recommend karyotype (20 cell) with reflex to microarray
 - a. Amnio preferred specimen after 15 weeks; fetal deep tissue sample preferred sample if declines amniocentesis; placenta last resort
5. Flow cytometry for fetal to maternal hemorrhage
6. Indirect coombs if not completed earlier in pregnancy and fetus not hydropic
7. Maternal toxicology screen
8. Parvovirus IgG and IgM; Syphilis screen
9. No other infection work up without clinical or histologic evidence
10. Lupus anticoagulant (IgG and IgM)
11. Beta 2 Glycoprotein antibody
12. HIV if not done

prenatally

Consider for some stillbirths

1. If severe placental pathology, IUGR, history of thrombosis, family history of thrombosis/emboli then consider Factor V Leiden, Prothrombin gene mutation, Protein C and S (at 6 weeks); Antithrombin III.
2. History of pruritus: Bile acids, LFTS
3. History of PPRM, cervical insufficiency or malpresentation, consider interval hydrosonography, MRI or HSG
4. Glucose (If LGA), Hgb A1C, Thyroid testing
5. Creatinine
6. If the fetus is dysmorphic or IUGR, even if the patient declines an autopsy, request a genetic consult and alert them that there is a fetus to be examined in the morgue.

Unlikely to be helpful

1. ANA
2. TORCH titers

In L&D, use the pre-packaged amniocentesis tray. Obtain at least 30 mL of fluid

(Label them to indicate which tube is #1, #2 and #3) Provide as much data as possible, including a description of the fetus. Package the tubes and label the transport bag "For cytogenetics". Leave a message on the cyto lab's answering machine (6-1595) indicating the name of the patient, indication of testing, and contact information.

Tissue sample
Place several ~10 mm pieces of the chorion containing villi and/or 2-3 cm of umbilical cord in the tube of **thawed** culture medium; If autopsy accepted, pathology can also send deep fetal tissue (such as paricardium or Achilles).



References

- 1) Alfirevic Z, Roberts D, Martlew V. How strong is the association between maternal thrombophilia and adverse pregnancy outcome? A systematic review. **Eur J Obstet Gynecol Reprod Biol** 2002;101:6-14. *Unexplained stillbirth, when compared with controls, was more often associated with heterozygous factor V Leiden mutation, protein S deficiency, activated protein C resistance, anticardiolipin IgG antibodies or lupus anticoagulant. Women with intrauterine growth restriction had a higher prevalence of heterozygous G20210A prothrombin gene mutation, homozygous MTHFR C677T gene mutation, protein S deficiency or anticardiolipin IgG antibodies than controls.*
- 2) Rey E, Kahn SR, David M, Shrier I. Thrombophilic disorders and fetal loss: a metaanalysis. **Lancet** 2003;361:901-8. *Late (greater than 20 weeks' gestation) nonrecurrent fetal loss is associated with factor V Leiden, prothrombin G20210A mutation, and protein S deficiency.*
- 3) Smulian JC, Ananth CV, Vintzeleos AM, Scorza WE, Knuppel RA. Fetal deaths in the United States. Influence of high-risk conditions and implications for management. **Obstet Gynecol** 2002;100:1183-9. *Diabetes is associated with a fetal loss rate of 3.6/1000 versus a low-risk pregnancy loss rate of 1.6/1000.*
- 4) Incerpi MH, Miller DA, Samadi R, Settlege RH, Goodwin TM. Stillbirth evaluation: what tests are needed? **Am J Obstet Gynecol** 1998;178:1121-5. *Feto-maternal hemorrhage was associated with 5% of fetal deaths.*
- 5) Ornoy A. The effects of alcohol and illicit drugs on the human embryo and fetus. **Isr J Psychiatry Relat Sci** 2002;39:120-32. *Cocaine use during pregnancy may apparently result in an increase in the rate of congenital anomalies, of stillbirth and of intrauterine growth retardation. The use of heroin and opiates does not seem to increase the rate of major congenital anomalies, but it reduces fetal growth and increases the rate of intrauterine fetal death.*
- 6) Smith NM. Broadsheet number 56: Mechanisms of fetal loss. **Pathology** 2000;32:107-15. *Chromosomal abnormalities are associated with 5-10% of late pregnancy losses.*
- 7) Petersson K, Bremme K, Bottinga R, et al. Diagnostic evaluation of intrauterine fetal deaths in Stockholm 1998-99. **Acta Obstet Gynecol Scand** 2002;81:284-92. *Infection was a contributing factor in stillbirth in 24% of cases. The most common pathogens were E. coli, Enterococcus, and GBS.*



- 8) Bryant Borders AE, Greenberg J, Plaga S, Shepard-Hinton M, Yates C, Elias S, Shulman LP. Fetal Diagn Ther. 2009;26(2):81-4. doi: 10.1159/000238114. Epub 2009 Sep 11. **Value of amniocentesis versus fetal tissue for cytogenetic analysis in cases of fetal demise.**
- 9) Thayyil S. Less invasive autopsy: an evidenced based approach. Arch Dis Child 2011 Jul; 96 (7):681-7.
- 10) Silver RM, Heuser CC. Stillbirth workup and delivery management. Clin Ob Gyn 2010; 53 (3):681-9.
- 11) Pinar H, Carpenter M. Placental and umbilical cord abnormalities seen with stillbirth Clinical Obstetrics and Gynecology Volume 53(3), September 2010, pp 656-67.
- 12) Management of Stillbirth. ACOG Practice Bulletin #102;2009. Reaffirmed 2012.
- 13) McPherson EM. Discovering the cause of stillbirth. Curr Opin Ob Gyn2013, 25.
- 14) Korteweg FJ, Bouman K, Erwich JJ, Timmer A, Veeger NJ, Ravisé JM, Nijman TH, Holm JP. Cytogenetic analysis after evaluation of 740 fetal deaths: proposal for diagnostic workup. Obstet Gynecol. 2008. Apr; 111(4): 865-74.

Revised July 2019 NVora.

This protocol is designed to assist the primary care provider in the clinical management of a variety of problems that occur during pregnancy. They should not be interpreted as a standard of care, but instead represent guidelines for management. Variation in practices should take into account such factors as characteristics of the individual patient, health resources, and regional experience with diagnostic and therapeutic modalities.

This protocol remains the intellectual property of the University of North Carolina at Chapel Hill School of Medicine. They cannot be reproduced in whole or in part without the expressed written permission of the school.